SSY Group Limited (LJUIF) Stock

About SSY Group Limited

SSY Group Limited functions as an investment holding company, primarily focused on the research, development, manufacturing, and distribution of a wide array of pharmaceutical goods. Its products reach hospitals and distributors across the People's Republic of China and international markets. The company's extensive product portfolio encompasses various intravenous (IV) infusion solutions, including formulations in non-PVC soft bags, upright soft bags, robust PP plastic bottles, and traditional glass bottles. It also provides ampoule and small volume injections, oral preparations, and both traditional Chinese and biological medicines. Furthermore, SSY Group supplies bulk pharmaceutical ingredients and essential medical materials. Beyond pharmaceuticals, the company engages in pharmaceutical technology research, development, and consulting services, alongside offering logistics support for its medical products. Uniquely, it also holds interests in the food, beverages, and catering sectors. Many of its offerings are marketed under the 'Shimen' brand. Established in 2004, the firm was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. before adopting the SSY Group Limited name in May 2015. It maintains its corporate headquarters in Wanchai, Hong Kong, and operates as a subsidiary of China Pharmaceutical Co., Ltd.

SSY Group Limited is headquartered in HK.

SSY Group Limited (LJUIF) stock trades at $0.40 with a market capitalization of $1.19B. The stock is valued at a price-to-earnings (P/E) ratio of 14.97, price-to-book of 0.96, price-to-sales of 1.67. Over the past 52 weeks the stock has ranged between $0.40 and $0.70, and currently trades 42.9% below its 52-week high. It pays a dividend yielding 2.50%.

On profitability, SSY Group Limited generates a return on equity (ROE) of 6.46%, return on capital employed of 6.17%, an operating margin of 15.10%, a net profit margin of 11.30%.

Official website: www.ssygroup.com.hk